Filter Results:
(926)
Show Results For
- All HBS Web
(1,279)
- People (5)
- News (171)
- Research (926)
- Events (6)
- Multimedia (12)
- Faculty Publications (758)
Show Results For
- All HBS Web
(1,279)
- People (5)
- News (171)
- Research (926)
- Events (6)
- Multimedia (12)
- Faculty Publications (758)
Sort by
- 10 Aug 2015
- Research & Ideas
New Medical Devices Get To Patients Too Slowly
While the US Food and Drug Administration has chiseled away pharmaceutical review times over the years to speed innovative drugs to market, the opposite seems to have occurred in the agency's approval of medical devices. Instead of... View Details
- Research Summary
Career Histories and the Biotechnology Industry
Professor Higgins' other major project focuses on the consequences of individuals' career experiences for firms and industries. This second research stream centers on the careers of executives in the biotechnology industry.
Professor Higgins has written... View Details
- September 2013 (Revised August 2015)
- Background Note
Leadership and Teaming
By: Ethan Bernstein
Small differences in the leadership of teams can have large consequences for the success of their efforts. Many initiatives fail not because of a fatal error in judgment or insufficient ideas, knowledge, motivation, or capabilities to deliver a solution. They fail... View Details
Keywords: Teams; Teaming; Leadership And Managing People; Leadership; Team Effectiveness; Team Performance; Team Design; Team Leadership; Teamwork; Team Process; Team Function; Team Launch; 60/30/10 Rule; Team Boundary; Distribution Of Leadership Authority; Self-Managed Teams; Virtual Teams; Unbounded Teams; Acts Of Leadership; Execution Teams; Decision Making Teams; Creativity Teams; Team Size; Task Design; Team Timeline; Team Roles; Team Representation; Diversity; Team Familiarity; Collective Intelligence; Team Stages Of Development; Team Coaching; Performance Pressure; X-Teams; Team Focus; Interaction; Management Teams; Managerial Roles; Management Systems; Management Style; Management Skills; Management Practices and Processes; Organizational Design; Organizational Structure; Performance Effectiveness; Performance Efficiency; Performance Productivity; Groups and Teams; Networks; Social Psychology; Behavior; Conflict and Resolution; Creativity; Social and Collaborative Networks; Satisfaction; Prejudice and Bias; Power and Influence; Personal Characteristics; Familiarity; Cognition and Thinking; Attitudes; Projects; Organizational Culture; Organizational Change and Adaptation; Leadership Development; Leadership Style; Leading Change; Knowledge Use and Leverage; Knowledge Sharing; Collaborative Innovation and Invention; Innovation and Management; Innovation Leadership; Design; Interpersonal Communication; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Asia; North and Central America; South America; Atlantic Ocean; Central Asia; Europe; Latin America; Middle East; Oceania; West Indies
Bernstein, Ethan. "Leadership and Teaming." Harvard Business School Background Note 414-033, September 2013. (Revised August 2015.)
- May 2020 (Revised March 2022)
- Case
The Coronavirus (COVID-19) Pandemic and the Global Economy (A)
By: Alberto Cavallo and Christian Godwin
In April 2020, the world struggled to contain the exponential escalation of the coronavirus (COVID-19) pandemic. Dozens of countries had imposed restrictions on travel, work, and social gatherings. A large share of the global population was under lockdowns and... View Details
Keywords: COVID-19 Pandemic; Demand and Consumers; Supply and Industry; Finance; Central Banking; Financial Markets; International Finance; Globalization; Government and Politics; Health Pandemics; Decision Making; Macroeconomics; Employment; Crisis Management; Supply Chain; Risk and Uncertainty; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Asia; China; Europe; Latin America; Africa; United States
Cavallo, Alberto, and Christian Godwin. "The Coronavirus (COVID-19) Pandemic and the Global Economy (A)." Harvard Business School Case 720-031, May 2020. (Revised March 2022.)
- 15 Jun 2007
- Research & Ideas
Remembering Alfred Chandler
Chemical and Pharmaceutical Industries. In his lifetime, he produced a range of books, edited collections, and articles covering railways, management, global competition, anthracite coal, the career of Alfred P. Sloan, the nature of... View Details
Keywords: by Sean Silverthorne
- 25 Apr 2005
- Research & Ideas
New Learning at American Home Products
pharmaceutical companies in 1984, American Home Products ranked first in sales and twenty-eighth in R&D expenditures as a percentage of sales.23 As the historian Williams Haynes noted, by the end of the 1930s, American Home Products... View Details
- 10 Sep 2008
- Research & Ideas
Long-Tail Economics? Give Me Blockbusters!
you can make money in many creative industries by selling specialized products to niche markets identified via the Internet. For example, the new CEO of GlaxoSmithKline, the pharmaceuticals giant, likens the search for blockbusters to... View Details
- 12 Dec 2022
- Research & Ideas
Buy-In from Black Patients Suffers When Drug Trials Don’t Include Them
Moderna, a pharmaceutical company, announced in September 2020 that it would slow enrollment of its COVID-19 vaccine trials to better improve representation. The majority of study participants were white, although COVID-19 was... View Details
- 31 Oct 2004
- Research & Ideas
Bypass Marketing: Are Docs Influenced?
Until the close of the last decade, health consumers received much of their knowledge and advice about prescription drugs from their physicians or other health care professionals. Today, pharmaceutical companies are spending several... View Details
Keywords: by Manda Salls
- 19 Sep 2017
- First Look
First Look at New Research and Ideas, September 19
717-426 Imprimis (A) This case examines the strategic choices and evolving business model of Imprimis Pharmaceuticals from the perspective of CEO Mark Baum. The (A) case provides a brief history of the company and of the compounding... View Details
Keywords: Sean Silverthorne
- 11 Sep 2019
- Research & Ideas
Germany May Have the Answer for Reducing Drug Prices
the Poronui Associate Professor of Business Administration. Pharmaceutical companies have long opposed efforts to regulate drug prices, arguing that prices reflect the companies’ massive research investments. But Germany’s approach shows... View Details
- 25 Jul 2005
- Research & Ideas
An Organization Your Customers Understand
pharmacy: a pharmaceutical company selling prescription drugs, and a consumer products company selling personal care products such as shampoo and beauty aids. A consumer filling a medical prescription or purchasing face cream would... View Details
Keywords: by Robert Simons
- 06 Feb 2007
- First Look
First Look: February 6, 2007
http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=806092 Endo Pharmaceuticals (A): From LBO to...? Harvard Business School Case 806-064 Endo Pharmaceuticals was formed in 1997 as a leveraged... View Details
Keywords: Martha Lagace
- 29 May 2001
- Research & Ideas
Genomics: Can We Start Making Money Now?
Now that scientists have mapped the human gene, can drug makers map a road to unlimited riches? For John Lechleiter, Executive Vice President of Eli Lilly and Company's Pharmaceutical Products and Corporate Development, there remain more... View Details
Keywords: by Sean Silverthorne
- 03 Dec 2001
- Research & Ideas
Healthcare Conference Looks At Ailing Industry
specified stage of development. It would throw the ball over the fence [to a major pharmaceutical firm] and it would sit around and wait. Sooner or later, if the product was successful, it would collect some royalties." Now, a... View Details
- 27 Jun 2005
- Research & Ideas
The Potential Downside of Win-Win
consideration for all managers. Value Creation—and Collusion Suppose that pharmaceutical firm A manufactures a new, beneficial drug and begins selling 100 million pills per year at $3.05 per pill. Each pill costs 5 cents to manufacture,... View Details
Keywords: by Max H. Bazerman
- 01 Sep 2020
- Cold Call Podcast
How to Launch a New Biosciences Product: Start Small or Dive in?
- November 1969 (Revised February 1973)
- Background Note
Note on the U.S. Prescription Drug Industry, Part II
By: Hugo Uyterhoeven and Audrey T. Sproat
Uyterhoeven, Hugo, and Audrey T. Sproat. "Note on the U.S. Prescription Drug Industry, Part II." Harvard Business School Background Note 370-039, November 1969. (Revised February 1973.)
- April 1998
- Case
Cephalon, Inc.
By: Peter Tufano
In early 1997, Cephalon, awaited an FDA panel's decision on whether its drug, Myotrophin, would be approved. If the drug was approved, the firm might need substantial additional funds to commercialize as well as to buy back rights to it (which had been sold earlier to... View Details
Keywords: Risk Management; Financing and Loans; Health Care and Treatment; Pharmaceutical Industry; United States
Tufano, Peter, Geoffrey Verter, and Markus Mullarkey. "Cephalon, Inc." Harvard Business School Case 298-116, April 1998.